Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1979 1
1980 4
1981 3
1982 8
1983 19
1984 10
1985 9
1986 18
1987 17
1988 27
1989 30
1990 47
1991 56
1992 81
1993 81
1994 72
1995 106
1996 139
1997 130
1998 121
1999 118
2000 123
2001 145
2002 116
2003 141
2004 122
2005 121
2006 121
2007 113
2008 109
2009 106
2010 106
2011 83
2012 94
2013 70
2014 83
2015 86
2016 74
2017 62
2018 63
2019 67
2020 74
2021 122
2022 154
2023 126
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

3,386 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for dumirox
Your search for dumyrox retrieved no results
Fluvoxamine and COVID-19.
El-Alfy AT, Busse K. El-Alfy AT, et al. WMJ. 2022;121:P2. WMJ. 2022. PMID: 35671339 Free article. No abstract available.
Fluvoxamine for symptomatic outpatients with COVID-19.
Wu PE, Austin E, Leong D. Wu PE, et al. CMAJ. 2022 Feb 22;194(7):E258. doi: 10.1503/cmaj.220011. Epub 2022 Jan 19. CMAJ. 2022. PMID: 35045990 Free PMC article. Review. No abstract available.
Lack of Benefit of Fluvoxamine for COVID-19.
Bhimraj A, Gallagher JC. Bhimraj A, et al. JAMA. 2023 Jan 24;329(4):291-292. doi: 10.1001/jama.2022.23954. JAMA. 2023. PMID: 36633871 No abstract available.
Fluvoxamine for COVID-19?
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 May 3;63(1623):69-70. Med Lett Drugs Ther. 2021. PMID: 33976099 No abstract available.
Fluvoxamine for the treatment of COVID-19.
Marzolini C, Marra F, Boyle A, Khoo S, Back DJ. Marzolini C, et al. Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1. Lancet Glob Health. 2022. PMID: 35180411 Free PMC article. No abstract available.
Fluvoxamine for the treatment of COVID-19.
Boulware DR, Abassi M. Boulware DR, et al. Lancet Glob Health. 2022 Mar;10(3):e329. doi: 10.1016/S2214-109X(21)00590-8. Lancet Glob Health. 2022. PMID: 35180409 Free PMC article. No abstract available.
Fluvoxamine for the treatment of COVID-19.
Kim H, Manzi S, Gonzelez-Heydrich J, Picker J. Kim H, et al. Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1. Lancet Glob Health. 2022. PMID: 35180410 Free PMC article. No abstract available.
Fluvoxamine for the treatment of COVID-19.
Dodds MG, Doyle EB, Reiersen AM, Brown F, Rayner CR. Dodds MG, et al. Lancet Glob Health. 2022 Mar;10(3):e332. doi: 10.1016/S2214-109X(22)00006-7. Lancet Glob Health. 2022. PMID: 35180412 Free PMC article. No abstract available.
Fluvoxamine for the treatment of COVID-19.
Nyirenda JL, Sofroniou M, Toews I, Mikolajewska A, Lehane C, Monsef I, Abu-Taha A, Maun A, Stegemann M, Schmucker C. Nyirenda JL, et al. Cochrane Database Syst Rev. 2022 Sep 14;9(9):CD015391. doi: 10.1002/14651858.CD015391. Cochrane Database Syst Rev. 2022. PMID: 36103313 Free PMC article. Review.
Fluvoxamine has not been approved for the treatment of infections, but has been used in the early treatment of people with mild to moderate COVID-19. ...We found no published studies comparing fluvoxamine to other pharmacological interventions of proven efficacy. .. …
Fluvoxamine has not been approved for the treatment of infections, but has been used in the early treatment of people with mild to mo …
3,386 results